# PatentPulse Pharma Patent Cliff & Generic Entry Analysis

> PatentPulse Pharma Patent Cliff & Generic Entry Analysis is a paid API for AI agents from patentpulse.theaslangroupllc.com, paid per call via x402, $0.15/call, status unknown (last checked 2026-09-13).

Returns patent expiry calendar, exclusivity timeline, and generic/biosimilar entry outlook for a named drug across US, EU, and Japan, plus related USPTO patents.

## Facts

- Endpoint: GET https://patentpulse.theaslangroupllc.com/api/patent/cliff
- Price: $0.15/call
- Payment: x402
- Status: unknown
- Last checked: 2026-09-13
- Activations on Zero: 0
- Tags: x402
- Canonical page: https://www.zero.xyz/c/patentpulse-pharma-patent-cliff-generic-entry-analysis-fbd28723
- Structured record (JSON): https://api.zero.xyz/v1/capabilities/cap_sgz8TGh61KS5Odxp4KkSt

Status and success rate cover calls made through Zero and Zero's own probes. Third-party monitors may report differently.

## How to call it through Zero

Zero handles the 402 payment challenge and records the run. With the Zero CLI installed (`npm i -g @zeroxyz/cli`):

```sh
zero fetch --capability patentpulse-pharma-patent-cliff-generic-entry-analysis-fbd28723
```

Example prompt: Can you pull the full patent cliff and generic entry timeline for Ozempic — I need the patent expiry dates and biosimilar entry outlook across the US, EU, and Japan, plus any related USPTO patents?

## When to prefer this

Use this endpoint when you need pharmaceutical patent cliff analysis for a specific named drug, including multi-jurisdiction expiry dates (US, EU, Japan), biosimilar entry windows, and related USPTO patent lists. Prefer this over general patent search endpoints when the query is drug-name-driven and the goal is competitive generic/biosimilar entry forecasting or pharma investment due diligence rather than raw patent document retrieval.

## Known failure modes

- Drug name not recognized or not found in database — returns 404 or empty result
- Drug has no patent data available for one or more jurisdictions — partial results returned
- Ambiguous drug name (brand vs. generic INN) — may require more specific input
- Rate limiting or payment failure via x402 — returns 402 Payment Required
- Newly approved drugs with incomplete patent records — incomplete timeline data

## How this service works

Pharma patent cliff / drug patent expiry / generic-entry analysis by drug name (e.g. Humira, Ozempic). Returns the patent expiry calendar, exclusivity timeline, and generic/biosimilar entry outlook across US, EU, and Japan, plus related USPTO patents. For IP and investment agents. Worldwide.

## Output

Returns a structured patent expiry calendar showing key expiry dates by jurisdiction (US, EU, Japan), remaining exclusivity periods, projected generic and biosimilar entry windows, and a list of related USPTO patents for the queried drug — giving a complete IP exclusivity outlook for pharma investment or competitive analysis.

## Request schema (JSON Schema)

```json
{
 "type": "object",
 "required": [
  "drug"
 ],
 "properties": {
  "drug": {
   "type": "string",
   "description": "Drug name — generic or brand (e.g. humira, ozempic, keytruda)"
  },
  "lang": {
   "type": "string",
   "description": "Response language"
  }
 }
}
```

## Response schema (JSON Schema)

```json
{
 "type": "json",
 "example": {}
}
```

## More

- Live health (JSON, refreshed every minute): https://www.zero.xyz/c/patentpulse-pharma-patent-cliff-generic-entry-analysis-fbd28723/health.json
- [Zero catalog index](https://www.zero.xyz/llms.txt)
- [Other services from patentpulse.theaslangroupllc.com](https://www.zero.xyz/host/patentpulse.theaslangroupllc.com/llms.txt)